“How fast does Ozempic work?” is one of the highest-volume search queries in the GLP-1 space. The honest research answer is more nuanced than the marketing answer. This article maps the week-by-week weight-loss trajectories observed in published phase 3 trials of semaglutide, tirzepatide, and retatrutide — and what the curves actually look like.
Weight loss is not linear
The most common misconception in popular framing is that weight loss in GLP-1 trials is uniform across the dosing period. The published trajectories show otherwise:
- Weeks 0–4: small weight loss (~1–3%) during dose titration
- Weeks 4–16: steepest rate of loss, ~1–1.5% per month
- Weeks 16–40: sustained but slowing rate
- Weeks 40–68: approaching plateau in most cohorts
STEP 1 (semaglutide) trajectory
From Wilding et al., NEJM 2021:
| Timepoint | Mean weight loss |
|---|---|
| Week 8 | ~4% |
| Week 20 | ~9% |
| Week 40 | ~13% |
| Week 68 (endpoint) | 14.9% |
The 9% milestone at 20 weeks reflects ~5 months of dosing. Substantial weight loss occurs in the first 4–5 months; the curve flattens thereafter as the metabolic system adapts.
SURMOUNT-1 (tirzepatide) trajectory
From Jastreboff et al., NEJM 2022 — 15 mg dose arm:
| Timepoint | Mean weight loss |
|---|---|
| Week 12 | ~7% |
| Week 24 | ~14% |
| Week 48 | ~20% |
| Week 72 (endpoint) | 22.5% |
Tirzepatide’s trajectory is steeper than semaglutide’s — likely a function of the dual GIP/GLP-1 activation. The curve still hasn’t fully plateaued at 72 weeks in the higher dose arms.
Retatrutide phase 2 trajectory
From Jastreboff et al., NEJM 2023 — 12 mg dose arm at 48 weeks: 24.2% weight loss. Critically, the curve was still descending — the trial endpoint was reached before any plateau. Phase 3 trials with longer duration are expected to show continued loss.
Why the dose titration period flattens early results
All three molecules require gradual dose escalation to manage gastrointestinal side effects:
- Semaglutide: 0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg (16-week titration)
- Tirzepatide: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg (20-week titration)
- Retatrutide: similar progressive titration in trial protocols
This is why “fast weight loss” claims need context — the first 12–16 weeks are largely titration weeks at sub-therapeutic doses. The largest weekly losses occur in months 4–10 once steady-state is achieved.
Individual response variance
Trial means hide significant individual variance. In SURMOUNT-1:
- ~50% of 15 mg participants lost ≥20%
- ~36% lost ≥25%
- ~15% lost <5% (low responders)
Genetic, behavioural, and dose-titration tolerance factors all contribute. The “average” trajectory masks substantial response heterogeneity.
What “fast” actually means in this class
Compared with traditional dietary intervention research (~2-5% loss at 12 months), GLP-1 agonists are fast. Compared with surgical research (~25-30% loss at 12 months for Roux-en-Y gastric bypass), they are slower. The class fills a middle position.
The plateau and what happens after
STEP 4 specifically tested withdrawal. Participants who stopped semaglutide at 20 weeks regained approximately two-thirds of the lost weight by week 68. Those who continued maintained loss. The metabolic adaptation drives weight regain in the absence of continued receptor activation.
Research takeaway
“Fast” is relative. The fastest-acting molecule in the class is retatrutide; the most-validated is semaglutide; the steepest trajectory in head-to-head comparison is tirzepatide. The plateau and regain dynamics are class-wide.
Chempeptides supplies HPLC-verified GLP-1 class peptides — see the catalogue.
Research use only. Trial data summarised from published peer-reviewed research literature.